Last reviewed · How we verify
artesunate-lapdap
artesunate-lapdap is a Antimalarial combination Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently FDA-approved for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions.
Artesunate-lapdap is a fixed-dose combination that combines an artemisinin derivative with a diaminopyrimidine antifolate to kill malaria parasites through complementary mechanisms.
Artesunate-lapdap is a fixed-dose combination that combines an artemisinin derivative with a diaminopyrimidine antifolate to kill malaria parasites through complementary mechanisms. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria treatment in endemic regions.
At a glance
| Generic name | artesunate-lapdap |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial combination |
| Target | Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Artesunate acts as a fast-acting blood schizonticide that rapidly reduces parasite biomass, while lapdap (chlorproguanil-dapsone) inhibits folate metabolism in the parasite, preventing DNA synthesis. The combination provides both rapid parasite clearance and sustained suppression, with potential for reduced resistance development compared to monotherapy.
Approved indications
- Uncomplicated malaria caused by Plasmodium falciparum
- Malaria treatment in endemic regions
Common side effects
- Gastrointestinal disturbances
- Headache
- Hemolytic anemia (in G6PD-deficient patients)
Key clinical trials
- Kintampo Trial of Combination Therapy for Malaria (PHASE4)
- Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria (PHASE2)
- Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria (PHASE3)
- Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children (PHASE3)
- Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi (PHASE4)
- Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- artesunate-lapdap CI brief — competitive landscape report
- artesunate-lapdap updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about artesunate-lapdap
What is artesunate-lapdap?
How does artesunate-lapdap work?
What is artesunate-lapdap used for?
Who makes artesunate-lapdap?
What drug class is artesunate-lapdap in?
What development phase is artesunate-lapdap in?
What are the side effects of artesunate-lapdap?
What does artesunate-lapdap target?
Related
- Drug class: All Antimalarial combination drugs
- Target: All drugs targeting Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Uncomplicated malaria caused by Plasmodium falciparum
- Indication: Drugs for Malaria treatment in endemic regions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing